Sanofi (SNY) Earns Media Sentiment Score of 0.15
News stories about Sanofi (NYSE:SNY) have trended somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sanofi earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.9242853109454 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- UPDATE 1-Mexico watchdog finds big pharma faces no competition on some drugs (feeds.reuters.com)
- Sanofi (SNY) Sues to Defend its Patent Rights on Lantus – StreetInsider.com (streetinsider.com)
- Dupixent Asthma Data Could Seal A Second Blockbuster Market – Seeking Alpha (seekingalpha.com)
Several brokerages have recently weighed in on SNY. Argus increased their price objective on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 9th. Cowen and Company reiterated a “market perform” rating and issued a $52.00 price objective (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Zacks Investment Research cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $63.75.
Sanofi (NYSE:SNY) traded down 0.35% during midday trading on Wednesday, reaching $47.75. 1,424,813 shares of the company traded hands. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24. The firm has a 50-day moving average of $48.11 and a 200-day moving average of $45.86. The stock has a market capitalization of $119.92 billion, a P/E ratio of 11.28 and a beta of 0.88.
Sanofi (NYSE:SNY) last released its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, analysts predict that Sanofi will post $3.23 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Sanofi (SNY) Earns Media Sentiment Score of 0.15” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/sanofi-sny-earns-media-sentiment-score-of-0-15/1466465.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.